A Phase 1/1b, Multicenter, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Pharmacodynamics, and Pharmacokinetics of ODC-IL2 Administered Via Intravenous Infusion in Adult Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs ODC IL2 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Trutino Biosciences
- 20 Jan 2025 New trial record